Insulin Aspart Injection (insulin aspart)

Biosimilar

Region: 🇪🇺 EU
Active substance: insulin aspart
Company: Masuu Pharma Europe Limited
Status: Application withdrawn
Therapeutic area: Diabetes Mellitus
Designations: Biosimilar
Application: EMEA/H/C/006720
ATC: A10AB05
Official record: www.ema.europa.eu

Indication

Treatment of diabetes mellitus

Regulatory milestones

Fri 17 Oct 2025🇪🇺 Application withdrawn (EU)

Insulin Aspart Injection (insulin aspart): EU application withdrawn

Masuu Pharma Europe Limited · source

Same substance in other markets

🇪🇺 Donrafylix Opinion · Kuraci
🇪🇺 Garzulys Opinion · Sciencepharma Sp. z o.o
🇪🇺 Dazparda Authorised · Sandoz GmbH
🇺🇸 Garzulys Approved · Emerge Bioscience Pte. Ltd.
🇪🇺 Truvelog Mix 30 Withdrawn · Sanofi Winthrop Industrie
🇪🇺 Kirsty (previously Kixelle) Authorised · Biosimilar Collaborations Ireland Limited
🇪🇺 Insulin aspart Sanofi Authorised · Sanofi Winthrop Industrie
🇪🇺 NovoRapid Authorised · Novo Nordisk A/S
🇪🇺 Ryzodeg Authorised · Novo Nordisk A/S
🇪🇺 NovoMix Authorised · Novo Nordisk A/S
🇪🇺 Fiasp Authorised · Novo Nordisk A/S

Follow Insulin Aspart Injection

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.